All In Biotech

Drug Trial Radar · NCT01976208

Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma

Last checked: Nov 20, 2026Latest source record: Dec 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

630

Actual

Start

Dec 2010

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose is to evaluate the safety and efficacy of recombinant humanized anti-IgE monoclonal antibody injection in patients with allergic asthma.

Conditions

  • Allergic Asthma

Interventions

  • OmalizumabDrug

    The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg,then dosing interval is every 2 weeks.

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with asthma exacerbationTime frame: 32 weeks

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • The Second Hospital of Jilin University

    Changchun, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Chongqing Xinqiao Hospital

    Chongqing, China

  • Chinese PLA Fuzhou General Hospital of Nanjing Military Command

    Fuzhou, China

  • South Hospital of South Medical University

    Guangzhou, China

  • Sir Run Run Shaw Hospital of Zhejiang University

    Hangzhou, China

  • The First Affiliated Hospital of Zhejiang University

    Hangzhou, China

  • The Second Affiliated Hospital of Zhejiang University

    Hangzhou, China

  • Chinese PLA Jinan Military General Hospital

    Jinan, China

  • Shandong Provincial Hospital

    Jinan, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Zhongda Hospital, Southeast University

    Nanjing, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • Qingdao Municipal Hospital

    Qingdao, China

  • Shanghai Changzheng Hospital

    Shanghai, China

  • Shanghai First People's Hospital

    Shanghai, China

  • Zhongshan Hospital, Fudan University

    Shanghai, China

  • Chinese PLA Shenyang Military Command General Hospital

    Shenyang, China

  • The First hospital of China Medical University

    Shenyang, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Second Hospital of Tianjin Medica University

    Tianjin, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology

    Wuhan, China

  • Xi'an Xijing Hospital

    Xi'an, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.